Phototherapy Lamps Market Size & Share Analysis - Growth Trends and Forecast (2027 - 2032)

Market Trends and Insights

Rising Incidence of Neonatal Jaundice, Premature Births, and Care Infrastructure

Neonatal jaundice creates a consistent clinical need for the phototherapy lamps market because light therapy remains a standard treatment option for newborns with elevated bilirubin. A 2025 study reported that neonatal jaundice affects 60% of full-term newborns and up to 80% of preterm newborns in the first week of life^[1]. A 2025 analysis of Global Burden of Disease data found that the age-standardized mortality rate for neonatal jaundice fell 56.8% between 1990 and 2021, while prevalence rose 41.5% during the same period. Better neonatal survival therefore increases the group of children who need monitoring and treatment, even when mortality declines. A 2026 Pediatric Research analysis reported that Sub-Saharan Africa and South Asia accounted for 68% of incident extreme hyperbilirubinemia cases and 90% of deaths in 2023. Demand in these regions depends on neonatal intensive care capacity, donor-supported procurement, and public investment in newborn care, which links equipment demand to wider health-system development.

Rising Burden of Psoriasis, Vitiligo, Eczema, and Other Photosensitive Disorders

The phototherapy lamps market is also supported by demand from dermatology settings, where narrowband UVB and excimer treatment are used for psoriasis, vitiligo, eczema, and related conditions. The American Medical Association CPT Editorial Panel approved updates to codes 96920-96922 that extend reimbursable targeted phototherapy indications to vitiligo, atopic dermatitis, and alopecia areata from January 1, 2027. STRATA Skin Sciences stated that the coverage change could expand the addressable patient group to more than 30 million people in the United States. Aetna’s clinical policy bulletin classified excimer laser, PUVA, and narrowband UVB as medically necessary for vitiligo after inadequate response to topical agents. A 2026 multicenter study reported an 85.5% response rate for XTRAC 308-nm excimer treatment combined with oral JAK inhibitors in pediatric progressive vitiligo, compared with 53.8% in a tacrolimus control group. These coverage and clinical developments support a broader role for supervised light treatment in specialty dermatology.

Migration From Fluorescent and Halogen Lamps to LED Phototherapy Lamps

The replacement of fluorescent and halogen equipment with LED systems creates demand that is not limited to changes in patient volumes. LED systems can be tuned to wavelengths relevant to bilirubin absorption, generally 450-475 nm, and narrowband UVB treatment, generally 311 nm for dermatology applications. Their lower thermal exposure and longer service life can reduce replacement-part use and biomedical engineering downtime for hospitals. Revised IEC 60601-2-50 requirements in 2025 added dose-precision and skin-burn-prevention requirements for infant phototherapy safety. These compliance factors favor equipment with consistent irradiance control and increase the value placed on LED performance. A 2025 study of next-generation LED therapeutic devices described improved safety, portability, and light distribution for wearable and implantable formats relative to bulkier legacy equipment^[2].

Growth of Home-Based, Portable, and Family-Centered Phototherapy

Homecare is changing how suppliers serve the phototherapy lamps market, especially in the United States. Cigna removed earlier restrictions on home phototherapy for 19.2 million covered lives in July 2025. Phothera reported that concurrent coverage changes by Cigna and Elevance Health opened restriction-free access to home devices for more than 66.7 million Americans with psoriasis, eczema, and vitiligo. The National Psoriasis Foundation also reported that Elevance Health revised home phototherapy coverage criteria after evidence on home narrowband UVB treatment^[3]. Smaller form factors, straightforward controls, remote dose monitoring, and physician oversight are increasingly important for products intended for home use. Family-centered neonatal designs make it possible to consider treatment models that reduce separation between newborns and caregivers while maintaining clinical supervision.

High Acquisition, Lifecycle, Safety, and Refurbished-Equipment Constraints

Advanced LED systems can require capital spending that public hospitals in lower-income settings find difficult to fund. The burden continues after purchase because calibration, recertification, replacement parts, and maintenance add to lifecycle costs. These constraints slow purchasing within the phototherapy lamps market where procurement decisions are tied to annual public budgets. A 2025 open-source device study found that a neonatal phototherapy unit meeting American Academy of Pediatrics and UNICEF irradiance specifications could be fabricated with USD 93.00 in material costs. The large cost difference between low-cost designs and commercial systems helps explain the continued use of refurbished equipment in South Asia, Sub-Saharan Africa, and parts of Latin America. Used equipment can defer new-device purchases and reduce replacement-cycle revenues. Safety considerations also remain material, particularly for homecare products, because dose accuracy, thermal exposure, and appropriate clinical supervision affect acceptance.

Stringent Device Approval and Clinical Compliance Requirements

Phototherapy device approval requirements vary by jurisdiction and add cost to product development in the phototherapy lamps market. In the United States, phototherapy systems are Class II medical devices that require Food and Drug Administration 510(k) clearance. The European Union’s Medical Device Regulation transition has extended product-registration timelines in some markets and gives larger suppliers an advantage when they have established regulatory resources. Portable and wearable systems can face added clinical validation requirements because their designs differ from traditional overhead units. Natus Sensory reported that TheraB Medical’s SnugLit wearable phototherapy device received Food and Drug Administration 510(k) clearance in January 2026 after a multiyear clinical validation process. Compliance with IEC 60601-2-50, Food and Drug Administration requirements, and European Union Medical Device Regulation requirements can become a barrier for smaller innovators and can favor acquisition or partnership as a route to commercialization.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Phototherapy Lamps Market Segment Analysis

LED lamps held 68.3% of revenue in 2026. Their position reflects targeted output at bilirubin-relevant wavelengths, longer operating life, lower heat exposure, and improved consistency compared with fluorescent alternatives. Hospitals are also giving more weight to irradiance precision because infant phototherapy safety requirements have strengthened. Fluorescent lamps remain in use in resource-constrained hospitals where installed systems can remain in service for long periods. UV lamps retain a specialist role in psoriasis, vitiligo, eczema, and atopic dermatitis care. Halogen lamps continue to lose relevance as hospitals replace older equipment during upgrade cycles.

LED lamps are forecast to grow at an 8.5% CAGR from 2027 to 2032, exceeding the total phototherapy lamps market growth rate. A 2025 European Journal of Pediatrics pilot study found that the Jauni wearable LED device enabled 83% of treated newborns to complete phototherapy within 48 hours. The device delivered irradiance of 25-30 µW/cm²/nm at 470 nm, and the study reported no serious adverse events. Wearable LED formats therefore widen the range of potential care settings without changing the clinical purpose of phototherapy. Suppliers can also use product tiers, from standard overhead lamps to connected premium systems, to address differing hospital, clinic, and homecare budgets.

Neonatal jaundice treatment accounted for 67.4% of the phototherapy lamps market size in 2026. The segment is anchored in the frequency of neonatal jaundice and the standard role of phototherapy in lowering bilirubin. Psoriasis represents the next major application, using narrowband UVB panels and 308-nm excimer devices in planned courses of care. Vitiligo treatment is gaining attention as payer policies and clinical evidence support phototherapy options. Eczema and atopic dermatitis can benefit from the January 2027 expansion of targeted-phototherapy reimbursement codes. Acne and cosmetic dermatology are served mainly by lower-priced consumer and semi-professional blue-light devices.

Neonatal jaundice treatment is forecast to grow at a 9.2% CAGR from 2027 to 2032, making it a central growth engine for the phototherapy lamps market. A 2026 analysis across 204 countries estimated that extreme hyperbilirubinemia in 2023 was associated with USD 6.9 billion-USD 10.4 billion in welfare losses and USD 13.0 billion in DALY-based human-capital losses. This burden reinforces the case for newborn screening and treatment capacity in South Asia and Sub-Saharan Africa. The Canadian Paediatric Society updated its position statement in March 2025 to introduce universal bilirubin screening. Screening protocols support continuing demand because hospitals need the capability to provide treatment when bilirubin results require action. The clinical urgency makes neonatal equipment purchases less discretionary than many other categories of capital equipment.

Hospitals and NICUs held 68.8% of revenue in 2026, reflecting the concentration of neonatal care and specialist dermatology services in institutional settings. These facilities require calibrated equipment, formal safety processes, and trained staff. Dermatology clinics form the second-largest end-user group, using narrowband UVB panels and 308-nm excimer systems within structured treatment courses. Hospital procurement remains important for overhead neonatal lamps and for higher-capacity dermatology equipment. Institutional buyers also value service support, compliance documentation, and integration with established care workflows. Homecare adoption is testing the historic dominance of in-clinic treatment as coverage policies change and equipment becomes simpler to use.

Homecare is forecast to grow at a 9.7% CAGR from 2027 to 2032. Phothera launched in January 2025 after combining Daavlin and National Biological Corporation, bringing together Food and Drug Administration-cleared narrowband UVB devices, ClearLink dosimetry controllers, and insurance navigation. This model combines equipment supply, connected dose control, and assistance with coverage decisions. Birth centers, community facilities, and rural health posts are a separate emerging user group where portable and battery-operated designs may be relevant. Their needs differ from those of specialty clinics because consistent grid power and biomedical support can be limited. Product design for these settings must balance portability, light output, durability, and safe operation.

Geography Analysis

North America

North America held 41.3% of the phototherapy lamps market in 2026. The region benefits from dense NICU capacity, established specialist dermatology networks, and insurance structures that support replacement demand. Cigna’s July 2025 policy update and Elevance Health’s related coverage revision expanded access to home phototherapy for psoriasis, eczema, and vitiligo. The changes increased the practical importance of residential procurement in a region previously led by institutional purchases. Natus Sensory and Canadian Hospital Specialties entered a multi-year agreement in February 2026 to expand access to newborn-care products across Canadian health systems. The agreement covers phototherapy, hearing screening, and NICU connectivity, showing how suppliers are combining product access with education and distribution. Food and Drug Administration clearance remains a central compliance factor for new products in the United States. The phototherapy lamps market has higher per-capita use in North America because of long-standing investment in neonatal and specialist care. Connected home devices are likely to be most relevant where payer coverage and remote clinical oversight are both available.

Asia-Pacific

Asia-Pacific is forecast to grow at a 7.5% CAGR from 2027 to 2032. High birth volumes, expanding NICU capacity, and greater access to specialist dermatology support the region’s demand profile. The region combines large public hospital systems with growing private care networks, creating demand across a broad range of price points. India’s device-production incentive framework and unmet neonatal-care needs support interest in lower-cost LED platforms for hospitals and community settings. Phoenix Medical Systems and Nice Neotech were identified in the supplied draft as domestic suppliers scaling affordable LED equipment. Japan and South Korea are more mature settings where interest is moving toward workflows that combine bilirubin measurement with phototherapy delivery. Regulatory requirements vary across the region and add complexity for international suppliers. The phototherapy lamps market size in Asia-Pacific is also shaped by the ability of providers to add capacity beyond major urban hospitals. Affordable LED equipment and portable formats are important where health systems are extending care to smaller facilities.

Europe, Middle East and Africa, and South America

Europe, the Middle East and Africa, and South America show different demand conditions within the wider phototherapy lamps market. Germany and France have supported wearable-phototherapy clinical trials, while European Union Medical Device Regulation compliance can lengthen registration processes and favor suppliers with established regulatory teams. The United Kingdom’s Photonet audit program tracks UVB treatment outcomes across Scottish dermatology centers, supporting procurement that emphasizes documented performance. Gulf Cooperation Council countries are investing in premium NICU infrastructure through hospital expansion and medical tourism. Sub-Saharan Africa has substantial unmet neonatal need, which supports the relevance of solar-powered and battery-operated LED solutions where electrification is limited. In South America, Brazil’s unified public health procurement system favors cost-competitive suppliers, including Fanem Ltda. Argentina’s macroeconomic volatility can interrupt capital-equipment purchasing across the region. These mixed geographies require suppliers to align product design, price, power requirements, and distribution support with local care capacity. European compliance factors, public purchasing rules, and infrastructure limits elsewhere can all affect the speed of adoption. The phototherapy lamps market share across these regions is therefore shaped less by a single purchasing model and more by local clinical capacity and procurement conditions.